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to 5,607 GBP/QALY. Adding SNS before SR corresponded to a QALY gain of 0.62, 
with ICUR 14,357 GBP/QALY. The most cost-effective treatment pathway for WSD 
patients was NASHA/Dx followed by SNS, with a maximum ICUR of 5,928 GBP/
QALY vs the other treatment pathways analysed. In comparison with treatment 
pathway excluding SNS, 0.55 QALY are gained. ConClusions: SNS is a relevant 
treatment for FI in patients who have failed conservative management. Including 
SNS into the treatment pathway for refractory FI may provide value-for-money 
in the UK NHS perspective.
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objeCtives: Implantable cardioverter-defibrillators (ICD) improve survival in 
heart failure patients with New York Heart Association Functional Classification 
(NYHA) class III/IV symptoms and a left ventricular ejection fraction (LVEF) of ≤ 35%. 
Therefore, the current clinical guidelines recommend the implantation of the ICD 
in all the patients that fulfill the above conditions. However, as the costs of the ICD 
devices are relatively high, the prophylactic implantation of ICDs as per the guide-
line is not particularly cost-effective. A previous study demonstrated that short-term 
variability of QT (STVQT) may in fact reflect the increased susceptibility to SCD in 
patients with DC since it was shown that patients with DC and HF had the highest 
STVQT. The objective of this study was to explore the cost–effectiveness of short-
term variability of QT (STVQT) as a biomarker for implanting ICDs as secondary 
prevention of SCDs in heart failure patients and assess the societal value (headroom) 
of a hypothetical perfect STVQT biomarker for risk assessment and subsequent 
treatment decision in implanting ICDs . Methods: The study uses a decision ana-
lytical model. Results: The use of the QT (STVQT) as a biomarker for implanting 
ICDs as secondary prevention of SCDs in heart failure patients is a cost-effective 
healthcare intervention. The headroom (societal willingness to pay multiplied by 
incremental quality-adjusted life years) available for the hypothetical perfect bio-
marker ranged from € 483 to € 3,868. ConClusions: The use of the QT (STVQT) as 
a biomarker for implanting ICDs is cost effective. Identification of patients with 
high-risk for SCD and implantation of ICDs only on those patients could potentially 
save substantial costs. However, further research of risk stratifying biomarkers test 
accuracy is needed to support and strengthen the results of this modeling study.
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objeCtives: A curative treatment for patients with Allergic Rhinitis (AR) is 
immunotherapy (IT). However, not all patients are susceptible for IT, and many 
patients currently receive this treatment without any effect. Component Resolved 
Diagnosis (CRD) is a technique that might help identifying susceptible patients 
for IT. This study aimed to evaluate the impact of diagnosing patients with AR 
with CRD on treatment prescription, costs and (health) outcomes compared 
to diagnosing patients with standard testing (Skin Prick Testing (SPT)) in the 
Netherlands. Methods: A literature search and interviews with experts were 
performed to structure a decision tree and to determine relevant parameters for 
the analysis. Parameter values were based on literature data; costs were retrieved 
from national databases. Primary outcomes were the incremental cost per addi-
tional full responder and the incremental cost per Quality Adjusted Life Year (QALY) 
over a time horizon of nine years. Results: Diagnosis through CRD increased the 
number of full responders to IT compared to diagnosing patients with SPT (13,239 
[95%CI; 10,039 – 16,868] vs 9,422 [95%CI; 7,384 – 11,891]). QALYs also increased more 
for patients on IT based on CRD compared to patients diagnosed with SPT (0.02734 
[95%CI; -0.0216 – 0.0338] vs 0.02362 [95%CI; 0.0201 – 0.0276]). Expected total costs per 
patient reduced when diagnosis took place with CRD, from € 7,555 [95%CI; € 7,496 
– € 7,618] to € 7,255 [95%CI; € 7,062 – 7,453]. The incremental cost per additional full 
responder and the incremental cost per Quality Adjusted Life Year (QALY) were 
€ -12,773 and € -80,667 respectively. The PSA showed that in 96.4% of the 10,000 simu-
lations CRD was dominant in both costs and additional full responders, and in 84.8% 
in both costs and additional QALYs. ConClusions: Using CRD in the diagnosis of 
patients with suspected AR seems to be both cost saving as improving treatment 
decisions and health outcomes.
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objeCtives: Cardiac resynchronization therapy (CRT) either via a pacing device 
(CRT-P) or a pacemaker-defibrillator device (CRT-D) is considered an effective treat-
ment for patients with congestive heart failure (CHF) and disturbances in heart 
rhythm (arrhythmias) having New York Heart Association (NYHA) class II, III and 
IV symptoms. However, due to the large numbers of patients, which do not get 
additional benefits from CRT-D, and also due to large costs of implementation and 
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objeCtives: Although self-administration “pen” devices offer certain advantages, 
their higher cost has prevented its wider dissemination in patients with diabe-
tes. The aim of this study was to determine their cost-effectiveness, compared 
to conventional vial and syringe, in adult patients in Colombia. Methods: We 
designed a cost-effectiveness Markov model, with annual cycles, five-year time 
horizon (with analysis at 3 and 10 years), 5% discount rate, and third party payer 
perspective (Colombian health system). Transition probabilities and utilities in 
quality adjusted life years (QALY) were obtained from a systematic review of the 
literature. Costs, in 2014 Colombian pesos (1 euro = 2,660 COP), were obtained 
locally from different sources (following the methodology proposed by IETS, the 
Colombian HTA agency). Cost-effectiveness threshold was three times per capita 
GDP (equivalent to € 17,547 per QALY). Results: The total cost of treating a patient 
with a syringe and vial over five years would be € 1,002, while the use of pen device 
would represent € 1,226. In the same period, the patient would gain 3.1709 and 
3.1849 QALY, respectively, representing an incremental cost effectiveness ratio 
(ICER) of € 15,302 per additional QALY gained. By extending the time horizon, 
the ICER lowers (€ 10,424 in 10 years). Different discount rates, from 0 to 12%, do 
not substantially alter the results. With a price reduction of 31% the pen device 
reaches the threshold of 1 per capita GDP. In the sensitivity analysis, the variables 
related to hypoglycemia (frequency and costs of treatment) are the ones that 
most modify the results. Cost-effectiveness, however, is maintained under dif-
ferent scenarios. ConClusions: Given the assumptions and limitations of this 
model, the pen-like devices for self-administration of insulin are cost-effective, 
compared with administration by vial and disposable syringes, in adult patients 
with diabetes in the Colombian context.
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objeCtives: Transcatheter aortic valve replacement (TAVR) is an important new 
therapy approach for the treatment of severe aortic stenosis. Our objective was to 
identify and review the growing body of published cost-effectiveness analyses of 
TAVR, and to identify opportunities for future modeling and analyses in light of 
new clinical evidence. Methods: A systematic search in PubMed, Embase, and 
HTA agency databases and a grey search were conducted for the period from 2005 
through 2014 to identify studies examining the cost-effectiveness of aortic valve 
replacement using a transcatheter-based intervention. Searches, study selection, 
and data extraction were performed according to a predefined protocol. We only 
included studies on cost-effectiveness of TAVR compared with either medical 
management (MM) or surgery (SAVR). Appraised studies were analyzed using the 
CHEERS checklist. Results: Our search yielded n= 15 studies, comprising 13 distinct 
decision-analytic models set in six countries: Belgium, Brazil, Canada, Spain, United 
Kingdom, and U.S.A. Four of the models were developed by national HTA agencies 
or academic groups. In some cases, HTA reports differed from the published results. 
Study quality per CHEERs criteria was poor to excellent. n= 7 models compared TAVR 
to medical management, two to surgery, and n= 5 evaluated the cost-effectiveness 
of TAVR in comparison to both. n= 13 studies utilized efficacy data from PARTNER 
A and B. Only one study used patient-level data in an “along-the-trial” design. ICER 
in studies comparing TAVR to MM ranged from £12,600 to US$115,600 per QALYs. 
Compared with SAVR, ICER estimates ranged from TAVR dominating to being domi-
nated. ConClusions: Economic evaluations are lagging behind published clinical 
evidence. Future opportunities include economic evaluation of newer clinical trial 
data, long-term follow-up data from earlier studies, and more explicit evaluation of 
subsets of patient cohorts. Overall model quality and reporting of methods including 
data sources could be improved further.
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objeCtives: To evaluate the cost-utility of including sacral nerve stimulation (SNS) 
in different treatment pathways for refractory fecal incontinence (FI). Methods: 
The treatment pathways of two populations, with a surgically repairable sphincter 
defect (SD) and without (WSD), were modeled through a patient-level simulation 
model. Three comparators to SNS were included: sphincter repair (SR), NASHA/
Dx and percutaneous tibial nerve stimulation. Colostomy or conservative treat-
ment were modeled as last resort. Clinical data were based on a systematic lit-
erature review and expert opinion (EO). Resource use was based on EO, whilst 
cost data were based on hospital costs and national tariff lists (GBP 2015-16). The 
UK NHS perspective (threshold: 30,000 GBP/QALY) and a lifetime horizon were 
adopted. Results: For SD patients, the most effective treatment pathway was 
SNS followed by SR, however it was not cost-effective vs SR followed by SNS (ICUR 
= 44,562 GBP/QALY). Adding SNS after or before SR was cost-effective vs SR only. 
In case of SNS used after SR the gain in QALY was equal to 0.48, with ICUR equal 
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objeCtives: To estimate the incremental cost-utility ratio (ICUR) for the use of a 
continuous infusion pump with integrated monitoring (SAP) compared with the 
application of multiple daily injections (MDI) in adult (> 15 year-old) patients with 
type 1 diabetes mellitus (DM1) in Colombia. Methods: We designed an annual 
cycle Markov model, with transition probabilities obtained from a systematic review 
of the literature. Outcomes included in the search were ketoacidosis, severe hypogly-
cemia, microvascular complications (retinopathy, nephropathy, neuropathy), quality 
of life (expressed in quality-adjusted life years, QALYs, and obtained from Tufts 
database), as well as mortality. Other features of the model were: discount rate 3.5% 
for costs and QALYs, third party payer perspective (only direct medical costs), and 
a lifespan time horizon (up to 55 years). Threshold used was three times per capita 
gross domestic product (GDP), equivalent to € 17,547. Costs were estimated in 2014 
Colombian pesos (1 euro = 2,660 COP), from base case scenarios (built by expert 
panels) and official tariff manuals. Univariate and probabilistic sensitivity analy-
sis were performed. Results: For the average patient, continuous infusion pump 
has a total expected cost of € 199,296, and generates 16.40 QALYs, while multiple 
daily injections would cost € 104737, and generate 14.48 QALYs (ICER € 49,302 per 
additional QALY gained). Sensitivity analysis shows that the only critical variable 
is the annual cost of continuous infusion pump treatment, which would have to 
be reduced by 40% to reach the cost-utility threshold. ConClusions: Under the 
assumptions of the model, treatment with continuous infusion pumps would not 
be cost-effective for the average adult DM1 patient in Colombia. Further analysis 
would be required, addressed to certain selected subgroups of patients.
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objeCtives: To evaluate cost-utility of HAL assisted TURB in comparison to TURB 
with WLC alone in patients with previously diagnosed NIMBC in Poland. Methods: 
Analysis was performed in 2014, from a public payer’s perspective with a lifetime hori-
zon. “HAL cost-effectiveness model in non-muscle invasive bladder cancer (NIMBC)” 
by Pharmerit Ltd. was adapted to Polish settings. The model consists of two parts: 
a short-term decision tree to assess outcomes of TURB and a Markov cohort model 
developed in order to examine long-term outcomes. Clinical efficacy of HAL was based 
on a systematic review of randomized clinical trials. Data concerning course of disease 
and standard of care in Poland were based on available observational studies, expert 
opinion and guidelines. Difference in utilization of resources between HAL assisted 
TURB and TURB with WLC alone was estimated on the basis of expert survey. Unit 
costs of drugs and medical procedures were based on Ministry of Health (MoH) and 
National Health Fund tariffs. Costs and effects were discounted at rates of 5% and 
3.5%, respectively. The cost-effectiveness threshold was set to 119,577 PLN accord-
ing to MoH requirements. Probabilistic sensitivity analyses (PSA) were conducted 
to assess the probability that HAL is cost-effective in Polish settings. Results: The 
difference in health outcomes between HAL assisted TURB and TURB with WLC alone 
was 0.034 QALY in favor of HAL. HAL assisted TURB was approximately 172 PLN more 
expensive than TURB with WLC alone. Incremental cost per QALY equaled 4,997 PLN. 
PSA indicated that HAL was cost-effective with probability of 95.9% and dominant 
with probability of 44.6%. ConClusions: Use of HAL to assist TURB is cost-effective 
in Poland when compared with TURB with WLC alone.
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objeCtives: To assess the cost-effectiveness and to project the clinical ben-
efits of sensor augmented pump (SAP) compared to continuous subcutane-
ous insulin infusion therapy alone (CSII), in type 1 diabetic patients (T1D), in 
Netherlands. Methods: The Core Diabetes Model was used to project the incidence 
of diabetes-related complications, based on a meta-analysis from Pickup comparing 
SAP vs CSII. In the Pickup meta-analysis, 70% sensor usage in a population with 
baseline HbA1c of 8.0% led to a reduction of -0.42% versus -0.10% HbA1c, for SAP and 
CSII respectively. The simulated population had a mean age of 27 years with a mean 
diabetes duration of 13 years. The quality of life was adjusted for a reduced fear of 
hypoglycaemic event in the SAP arm. A discount rate of 4% and 1.5% for respec-
tively economic and clinical outcomes was applied. Several sensitivity analysis 
were conducted on key parameters. Results: The incremental cost-effectiveness 
ratio (ICER) was 22,335 € per Quality Adjusted Life Year gained (QALY) based on 
a societal perspective. The improvement in discounted QALY was 1.768 years in 
favor of SAP. SAP additional related costs were partially offset by the savings due to 
the reduction in diabetes long-term complications and lower frequency of SMBG. 
Reduction in the incidence (%) and delay of onset of diabetes complications (years) 
were achieved with SAP compared to CSII alone, such as neuropathy (13% 1.3 years), 
first ulcer (5% 1.19 years) and stroke (4% 0.81 years). The acceptability curve showed 
that the likelihood to be cost-effective at a willingness to pay of 80,000 € /QALY 
was 100%. ConClusions: These results indicate that accordingly to commonly 
accepted threshold SAP compared to CSII alone can be considered as very good 
value for money in the Dutch setting. Extensive sensitivity analysis on key drivers 
confirmed the robustness of results.
follow-up this may not always be the most cost-effective alternative. In fact, eco-
nomic evaluations have shown that incremental cost-effectiveness ratios (ICERs) 
of CRT-D may be substantially higher than for comparators. A recent study dem-
onstrated that certain biomarkers may in fact reflect the increased susceptibility 
to SCD in patients with HF and this may further contribute to increase cost-effec-
tiveness of the CRT-D interventions. The objective of this study was to explore the 
cost–effectiveness of a hypothetical perfect biomarker for risk assessment and sub-
sequent treatment decision in implanting CRT-Ds in heart failure patients who com-
ply with the current clinical guidelines and assess the societal value (headroom) of 
such test. Methods: The study uses a decision analytical model. Results: The use 
of a hypothetical perfect biomarker for implanting CRT-Ds in heart failure patients is 
a cost-effective healthcare intervention. The headroom (societal willingness to pay 
multiplied by incremental quality-adjusted life years) available for the hypothetical 
perfect biomarker ranged from € 1,530 to € 6,120 depending on the willingness to pay 
threshold. ConClusions: The use of a hypothetical perfect biomarker for implant-
ing CRT-D is cost effective. Substantial cost can be saved by a better identification of 
patients with high-risk for SCD and for whom implantation of CRT-Ds reduces risks 
of death. However, further research of risk stratifying biomarkers test accuracy is 
needed to support and strengthen the results of this modeling study.
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objeCtives: To investigate the long-term cost-effectiveness of initiating transanal 
irrigation* (TAI) as second-line management in patients with neurogenic bowel 
dysfunction (NBD) who have failed first-line standard bowel care (SBC). Methods: 
A deterministic Markov decision model was developed to project the lifetime health 
economic outcomes, including quality-adjusted life expectancy (QALE), episodes 
of faecal incontinence (FI), urinary tract infections (UTIs), and stoma surgery when 
using TAI relative to continuing SBC. Patients could transition from TAI to (a) another 
round of first-line SBC, (b) third-line surgeries (sacral nerve stimulator, sacral ante-
rior root stimulator, antegrade continence enema) or (c) stoma as the absorbing 
state. Transition probabilities and QALE estimates were based on real-world data 
collected at three clinics in UK from 2007-2014, in NBD patients due to spinal cord 
injury (SCI), multiple sclerosis, spina bifida, and cauda equina syndrome. Transition 
probabilities for failed SBC patients were collected from 2000-2007 prior to avail-
ability of TAI. Projected life-expectancy was based on published SCI population data. 
One-way sensitivity analyses were applied. Results: The model predicts that a SCI 
patient diagnosed aged 30, with a life expectancy of 37 years using TAI, will experi-
ence a 36.1% reduction in FI, 28.7% reduction in UTIs, a 35.4% reduction in stoma 
surgery and improvement of 0.40 years of QALE, compared with patients continuing 
SBC. Lifetime cost-savings of £41,620 per patient was estimated for TAI versus SBC 
in a SCI patient, primarily due to avoided hospitalizations and stoma surgeries. 
Incremental cost can differ due to altered life-expectancy (and age of diagnosis) in 
the patient cohort. One-way sensitivity analyses indicated that the model was most 
sensitive to variation in utilities on TAI and SBC treatment. ConClusions: TAI is a 
cost-saving treatment strategy reducing risk of stoma surgery and improving QALE 
for NBD patients who have failed SBC. *Peristeen (Coloplast A/S).
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objeCtives: To assess the reduction of complications and costs with continu-
ous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in 
uncontrolled type 2 diabetic patients (T2D) in the UK. Methods: The incidence of 
diabetes-related complications was calculated based on the Core Diabetes Model. 
The population characteristics, the reduction of HbA1c, and insulin dose were based 
on the Opt2mise study (Reznik et al., Lancet 2014) (mean age 56 years (SD 9.6); mean 
diabetes duration 15 years (SD 0.75)). For a baseline HbA1c of 9.0%, the reduction in 
HbA1c was -1.1 % versus -0.4%, respectively, for CSII vs MDI. Costs were UK-specific 
and expressed in £2014. Results: The diabetes-related complications were reduced 
with CSII. At 5 years, the incidence reduction in complications associated with eye dis-
eases, renal diseases, ulcer/amputation and cardiovascular diseases were -24%, -26%, 
-19% and -10%, respectively, in favour of CSII. This equates to a cost reduction of 12% 
over 5 years per patient. End stage renal disease was delayed by 1 year, neuropathy by 
1.08 years and amputation by 0.87 year, myocardial infarction and stroke by 0.81 and 
0.71 year respectively. Insulin dose was reduced for patients on CSII from 122.1 IU to 
96.5 IU per day with a cost saving of £2,169 per patient over 5 years. ConClusions: 
Improvements in HbA1c with a decrease in overall insulin requirements observed 
with CSII versus MDI, may offer important reductions in diabetes-related complica-
tions and associated costs in a UK setting for uncontrolled T2DM patients.
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